Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

OCTOBER 1, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. For more information, please visit www.virpaxpharma.com. About Noble Capital Markets, Inc.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

The Cannigma

MAY 7, 2021

This is where the crux of the issue is, if you are a patient then you have epilepsy or your child has epilepsy, you want a qualified product that you can rely on that has the same level of provision in relation to the manufacturing process as any other medicine that you would take.

Supply Chain 126

Supply Chain Patients Access Hemp 126

Alchimia

FEBRUARY 1, 2022

This molecule, which has found huge popularity in recent years due to its therapeutic potential, has led not only the scientific community to focus on its study, but also seed banks to strive to create new varieties rich in CBD, strains with different THC/CBD ratios designed to meet the needs of a growing public. Drowsiness. Mild fatigue.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 5, 2022

3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

The Cannigma

MARCH 12, 2021

There are no payment systems, there’s no banking and cannabis. We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. So, for example, payment systems.

Legalization 132

Legalization Patients Education Dispensary 132